MedWatch

Hansa Biopharma signs deal with US-based gene therapy firm

Swedish biotech firm Hansa Biopharma signs million-dollar deal with US-based gene therapy company Sarepta. The deal ensures Hansa Biopharma gets USD 10 million and milestone payments of up to USD 397.5 million.

Photo: Hansa Biopharma

There are many reasons to smile in the Swedish biotech firm Hansa Biopharma these days.

The company recently announced a license agreement with US-based gene therapy firm Sarepta giving the US company license to develop the Swedish company’s main asset, imlifidase, as a potential pre-treatment for certain patients prior to gene therapy in two rare diseases.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles